npj Parkinson's Disease (Feb 2017)

Elevated 5hmC levels characterize DNA of the cerebellum in Parkinson’s disease

  • Reinhard Stöger,
  • Paula J. Scaife,
  • Freya Shephard,
  • Lisa Chakrabarti

DOI
https://doi.org/10.1038/s41531-017-0007-3
Journal volume & issue
Vol. 3, no. 1
pp. 1 – 3

Abstract

Read online

Abstract 5-methylcytosine and the oxidation product 5-hydroxymethylcytosine are two prominent epigenetic variants of the cytosine base in nuclear DNA of mammalian brains. We measured levels of 5-methylcytosine and 5-hydroxymethylcytosine by enzyme-linked immunosorbent assay in DNA from post-mortem cerebella of individuals with Parkinson’s disease and age-matched controls. 5-methylcytosine levels showed no significant differences between Parkinson’s disease and control DNA sample sets. In contrast, median 5-hydroxymethylcytosine levels were almost twice as high (p < 0.001) in both male and female Parkinson’s disease individuals compared with controls. The distinct epigenetic profile identified in cerebellar DNA of Parkinson’s disease patients raises the question whether elevated 5-hydroxymethylcytosine levels are a driver or a consequence of Parkinson’s disease.